{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:46:26Z","timestamp":1774406786383,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"DOI":"10.7759\/cureus.72400","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T02:09:56Z","timestamp":1729908596000},"source":"Crossref","is-referenced-by-count":5,"title":["Impact of Malnutrition on the Length of Stay for Hospitalized Chimeric Antigen Receptor T-cell (CAR-T) Therapy Patients in the United States (2020)"],"prefix":"10.7759","author":[{"given":"Tong","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olu","family":"Oyesanmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman","family":"Muddassir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al.. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018, 378:439-48. 10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017, 377:2531-44. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June CH","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018, 379:64-73. 10.1056\/NEJMra1706169","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al.. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019, 20:31-42. 10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al.. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019, 380:45-56. 10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay KA","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, et al.. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017, 130:2295-306. 10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust J","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, et al.. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017, 7:1404-19. 10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling S","year":"2010","unstructured":"von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010, 1:1-5. 10.1007\/s13539-010-0002-6","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12(5)","author":"Fearon K","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al.. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12(5):489-495. 10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0148607108325076","article-title":"Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group","volume":"33","author":"Bozzetti F","year":"2009","unstructured":"Bozzetti F, Mariani L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr. 2009, 33:361-7. 10.1177\/0148607108325076","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos VE","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KC. Cancer-associated cachexia. Nat Rev Dis Primers. 2018, 4:17105. 10.1038\/nrdp.2017.105","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37 Suppl 1","author":"Neelapu SS","year":"2019","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019, 37 Suppl 1:48-52. 10.1002\/hon.2595","journal-title":"Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-95. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso BD","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, et al.. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018, 8:958-71. 10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2287","article-title":"Nutrition challenges of cancer cachexia","volume":"45","author":"Gaafer OU","year":"2021","unstructured":"Gaafer OU, Zimmers TA. Nutrition challenges of cancer cachexia. JPEN J Parenter Enteral Nutr. 2021, 45:16-25. 10.1002\/jpen.2287","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0737-8","article-title":"Metabolic and nutritional support of critically ill patients: consensus and controversies","volume":"19","author":"Preiser JC","year":"2015","unstructured":"Preiser JC, van Zanten AR, Berger MM, et al.. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015, 19:35. 10.1186\/s13054-015-0737-8","journal-title":"Crit Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605578","article-title":"Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres","volume":"102","author":"Pressoir M","year":"2010","unstructured":"Pressoir M, Desn\u00e9 S, Berchery D, et al.. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010, 102:966-71. 10.1038\/sj.bjc.6605578","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2024.05.020","article-title":"Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival","volume":"62","author":"Cucchiaro B","year":"2024","unstructured":"Cucchiaro B, Davies NA, Weekes CE, O'Reilly M, Roddie C, Slee A. Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival. Clin Nutr ESPEN. 2024, 62:206-15. 10.1016\/j.clnesp.2024.05.020","journal-title":"Clin Nutr ESPEN"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski K","year":"2023","unstructured":"Rejeski K, Cordas Dos Santos DM, Parker NH, et al.. Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Cancer Immunol Res. 2023, 11:707-19. 10.1158\/2326-6066.CIR-22-0487","journal-title":"Cancer Immunol Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18054","article-title":"Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"197","author":"Roy I","year":"2022","unstructured":"Roy I, Smilnak G, Burkart M, et al.. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022, 197:71-5. 10.1111\/bjh.18054","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends J","year":"2017","unstructured":"Arends J, Baracos V, Bertz H, et al.. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017, 36:1187-96. 10.1016\/j.clnu.2017.06.017","journal-title":"Clin Nutr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1440","article-title":"GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community","volume":"43","author":"Jensen GL","year":"2019","unstructured":"Jensen GL, Cederholm T, Correia MI, et al.. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. JPEN J Parenter Enteral Nutr. 2019, 43:32-40. 10.1002\/jpen.1440","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tipsro.2020.10.001","article-title":"Sarcopenia in cancer: risking more than muscle loss","volume":"16","author":"Anjanappa M","year":"2020","unstructured":"Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, Choudhury A. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020, 16:50-7. 10.1016\/j.tipsro.2020.10.001","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy231","article-title":"Impact of sarcopenia on adverse outcomes after allogeneic hematopoietic cell transplantation","volume":"111","author":"Armenian SH","year":"2019","unstructured":"Armenian SH, Xiao M, Berano Teh J, et al.. Impact of sarcopenia on adverse outcomes after allogeneic hematopoietic cell transplantation. J Natl Cancer Inst. 2019, 111:837-44. 10.1093\/jnci\/djy231","journal-title":"J Natl Cancer Inst"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.01.006","article-title":"Body weight loss before allogeneic hematopoietic stem cell transplantation predicts survival outcomes in acute leukemia patients","volume":"27","author":"Tamaki M","year":"2021","unstructured":"Tamaki M, Nakasone H, Nakamura Y, et al.. Body weight loss before allogeneic hematopoietic stem cell transplantation predicts survival outcomes in acute leukemia patients. Transplant Cell Ther. 2021, 27:340.e1-6. 10.1016\/j.jtct.2021.01.006","journal-title":"Transplant Cell Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.10.015","article-title":"Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy","volume":"46","author":"Cucchiaro B","year":"2021","unstructured":"Cucchiaro B, Weekes CE. Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. Clin Nutr ESPEN. 2021, 46:60-5. 10.1016\/j.clnesp.2021.10.015","journal-title":"Clin Nutr ESPEN"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241261558","article-title":"Racial and ethnic disparities in cancer occurrence and outcomes in rural United States: a scoping review","volume":"31","author":"Njoku A","year":"2024","unstructured":"Njoku A, Sawadogo W, Frimpong P. Racial and ethnic disparities in cancer occurrence and outcomes in rural United States: a scoping review. Cancer Control. 2024, 31:10732748241261558. 10.1177\/10732748241261558","journal-title":"Cancer Control"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.5.334","article-title":"Racial and ethnic disparities in the receipt of cancer treatment","volume":"94","author":"Shavers VL","year":"2002","unstructured":"Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002, 94:334-57. 10.1093\/jnci\/94.5.334","journal-title":"J Natl Cancer Inst"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411606","article-title":"Racial differences in the treatment of early-stage lung cancer","volume":"341","author":"Bach PB","year":"1999","unstructured":"Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999, 341:1198-205. 10.1056\/NEJM199910143411606","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c0263d","article-title":"Nutrition therapy in the critical care setting: what is \"best achievable\" practice? An international multicenter observational study","volume":"38","author":"Cahill NE","year":"2010","unstructured":"Cahill NE, Dhaliwal R, Day AG, Jiang X, Heyland DK. Nutrition therapy in the critical care setting: what is \"best achievable\" practice? An international multicenter observational study. Crit Care Med. 2010, 38:395-401. 10.1097\/CCM.0b013e3181c0263d","journal-title":"Crit Care Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278442-impact-of-malnutrition-on-the-length-of-stay-for-hospitalized-chimeric-antigen-receptor-t-cell-car-t-therapy-patients-in-the-united-states-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T02:09:59Z","timestamp":1729908599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278442-impact-of-malnutrition-on-the-length-of-stay-for-hospitalized-chimeric-antigen-receptor-t-cell-car-t-therapy-patients-in-the-united-states-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.72400","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}